Eli Lilly Net Worth 2010-2023 | LLY

Interactive chart of historical net worth (market cap) for Eli Lilly (LLY) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Eli Lilly net worth as of April 17, 2024 is $709.53B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $709.526B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $553.986B 45.64
Johnson & Johnson (JNJ) United States $348.093B 13.81
Merck (MRK) United States $316.781B 83.37
AbbVie (ABBV) United States $287.801B 14.63
AstraZeneca (AZN) United Kingdom $211.650B 18.75
Novartis AG (NVS) Switzerland $197.547B 13.69
Pfizer (PFE) United States $145.471B 14.04
Sanofi (SNY) $115.856B 10.43
Innoviva (INVA) United States $0.915B 6.46